Evidence map›Paper›PMID 41086194›Full record

ArticlePLoS pathogens2025

UBXN7 facilitates SARS-CoV-2 replication via inhibiting the K48-linked ubiquitination of viral N protein.

Tian Xia, Min Luo, Yuncheng Wang, Yaping Qin, Xiaoning Li, Shuying Chen, Junqi Xiang, Shanrong Yang, Yaokai Wang, Jing Zhu and 9 more

Abstract read
In one paragraph

Article in PLoS pathogens, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Tian XiaCollege of Basic Medicine, Chongqing Medical University, China.
Min LuoInstitute of Pathology, Southwest Hospital, Third Military Medical University (Army Medical University), and Key Laboratory of Tumor Immunopathology, Ministry of Education of China, Chongqing, China.
Yuncheng WangCollege of Basic Medicine, Chongqing Medical University, China.
Yaping QinHenan Institute of Medical and Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, China.
Xiaoning LiCollege of Basic Medicine, Chongqing Medical University, China.
Shuying ChenCollege of Basic Medicine, Chongqing Medical University, China.
Junqi XiangCollege of Basic Medicine, Chongqing Medical University, China.
Shanrong YangCollege of Basic Medicine, Chongqing Medical University, China.
Yaokai WangCollege of Basic Medicine, Chongqing Medical University, China.
Jing ZhuCollege of Basic Medicine, Chongqing Medical University, China.
Bo YangCollege of Basic Medicine, Chongqing Medical University, China.
Li LinDepartment of Respiratory Children's Hospital of Chongqing Medical University, National Clinical Research Center for Child Health and Disorders, Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing Key Laboratory of Child Rare Diseases in Infection and Immunity, China.
Jiajun YanCollege of Basic Medicine, Chongqing Medical University, China.
Yunxiao DouCollege of Basic Medicine, Chongqing Medical University, China.
Jian ShangHenan Institute of Medical and Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, China.
Na ZangDepartment of Respiratory Children's Hospital of Chongqing Medical University, National Clinical Research Center for Child Health and Disorders, Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing Key Laboratory of Child Rare Diseases in Infection and Immunity, China.
Yong LinKey Laboratory of Molecular Biology of Infectious Diseases (Chinese Ministry of Education), Chongqing Medical University, China.
Xiaohong YaoInstitute of Pathology, Southwest Hospital, Third Military Medical University (Army Medical University), and Key Laboratory of Tumor Immunopathology, Ministry of Education of China, Chongqing, China.
Yushun WanCollege of Basic Medicine, Chongqing Medical University, China.ORCID 0000-0003-0496-6315

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Host factor-mediated post-translational modification of coronavirus proteins has been demonstrated as an important strategy for regulating viral proliferation. Identification of key host genes involved in this process may provide potential therapeutic targets. In this study, we used the complementary reverse genetic system to determine that UBXN7 promotes SARS-CoV-2 viral double-stranded RNA (dsRNA) production and also promotes the replication of other human coronaviruses. However, UBXN7 does not affect the replication of VSV and RSV, suggesting that it may be a potential pan human coronaviral anti-infection target. Our results revealed that UBXN7 did not affect the viral invasion of cells, but instead hijacked viral genome assembly by interacting with SARS-CoV-2 N protein via its UBX domain. Further data indicated that UBXN7 inhibits K48-linked ubiquitination and proteasomal degradation of SARS-CoV-2 N protein, leading to N protein accumulation. Moreover, K257 of N protein was identified as specific target site of UBXN7 which are critical for viral replication. These findings reveal a novel relationship between host gene-mediated protein ubiquitylation and viral genome assembly, providing new strategies for potential pan-coronavirus drug design.

Indexed as

Coronavirus Nucleocapsid ProteinsCOVID-19SARS-CoV-2Virus ReplicationAnimalsChlorocebus aethiopsHEK293 CellsHumansUbiquitinationVero CellsCoronavirus Nucleocapsid Proteins

Identifiers

PMID41086194
PMCPMC12520364

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.